Non-viral GMP manufacturing for engineered cells at clinical and commercial scale

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Non-viral GMP manufacturing for engineered cells at clinical and commercial scale

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Conventional viral and non-viral gene-editing technologies can pose challenges for the development of cell therapies that require the efficient delivery of multiple payloads while maintaining the quality of cells at scale. In this webinar, we introduce a fully validated, non-viral GMP gene-editing platform that enables efficient co-delivery of multiple payloads with high performance across research and commercial manufacturing scales.

Attendees will learn about a cellular engineering platform that delivers high yields of gene-edited cells to produce the final drug substance in a cost-efficient manner. This technology combines mechanical, electrical, and chemical forces to effect efficient genome engineering of cells. It allows the adjustment of multiple parameters to maximize transfection efficiency, cell health, and yield, while continuous flow enables the processing of liters of material in a closed, automated system to generate billions of high-quality edited cells in minutes.

Learn about how seamless transition from the high-throughput, low-volume screening system to the commercial-scale platform reduces development time and eliminates traditional scale-up bottlenecks such as batch processing, providing a foundation for streamlining cell therapy manufacturing from development through commercial production.

Learn about how a fully validated, GMP-compliant, commercial-scale platform can maximize cell yields, delivering hundreds of billions of cells in minutes – faster than any other technology
Find out how mechanical, electrical, and chemical forces can be combined to effect efficient gene transfer into cells
Discover how continuous flow enables the processing of liters of material in a closed, automated system in minutes

Leif Anderson

Associate Director, Field Applications Scientist at Kytopen

Leif Anderson is an Associate Director, Field Applications at Kytopen. Leif completed his PhD in Biomedical Engineering at UC Davis in 2018. During his six years as a Field Application Scientist in the cell and gene engineering space, Leif has made significant contributions to companies such as LUMICKS, NanoView Biosciences, Unchained Labs, and MaxCyte. His passion lies in supporting customer research by helping scientists and researchers utilize cutting-edge technology to advance their work.

Chris Abraham

Director, Applications Scientist at Kytopen

Chris is the Director of Applications at Kytopen. He completed his PhD in Microbiology at the University of Colorado Anschutz Medical Campus in 2014. Chris went on to complete his American Cancer Society funded post-doctoral studies at the University of Colorado at Boulder, focused on developing genome-scale, CRISPR-based, methodologies to power functional genomic studies in cancer models. Following his post-doctoral studies, Chris joined Muse Bio, now Inscripta, to engineer and characterize novel genome engineering components for deployment in both microbial and mammalian cells. He then moved to Artisan Bio, where he built multiple high-throughput screening platforms to engineer novel, CRISPR-based technologies and leverage precise knock-in performances to build massively multiplexed data to optimize CAR-T cell characteristics for therapeutic applications.